Scarica l'app Stockscreener
1.34
2.90%
-0.04
Dopo l'orario di chiusura:
1.34
Precedente Chiudi:
$1.38
Aprire:
$1.36
Volume 24 ore:
38,935
Relative Volume:
0.32
Capitalizzazione di mercato:
$20.74M
Reddito:
$321.50K
Utile/perdita netta:
$-7.24M
Rapporto P/E:
-0.7658
EPS:
-1.7498
Flusso di cassa netto:
$-5.72M
1 W Prestazione:
+3.08%
1M Prestazione:
-26.37%
6M Prestazione:
-35.89%
1 anno Prestazione:
-5.13%
Intervallo 1D:
$1.32
$1.40
Intervallo di 1 settimana:
$1.3001
$1.43
Portata 52W:
$1.25
$3.62
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
22211 WEST INTERSTATE-10, SAN ANTONIO
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development - Zenopa
BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer - TipRanks
bioAffinity appoints new Chief Science Officer By Investing.com - Investing.com UK
J. Michael Edwards Named CFO at bioAffinity Technologies - MPO-mag
SA company sets the stage for Asian expansion - The Business Journals
bioAffinity’s CyPath Lung Test Now Available to U.S. Veterans - MPO-mag
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung - Zenopa
bioAffinity secures Japanese patent for lung health test By Investing.com - Investing.com South Africa
BIAFbioAffinity Technologies, Inc. Latest Stock News & Market Updates - StockTitan
bioAffinity secures Japanese patent for lung health test - Investing.com
bioAffinity Technologies Closes of $2.6 Million Registered Direct Offering & Concurrent Private Placement - citybiz
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
SEC Form 424B5 filed by bioAffinity Technologies Inc. - Quantisnow
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity Technologies Prices of $2.66 Million Registered Direct Offering & Concurrent Private Placement - citybiz
BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement - MarketWatch
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity VP contributes to new cytometry guidelines - Investing.com
bioAffinity VP contributes to new cytometry guidelines By Investing.com - Investing.com South Africa
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines - StockTitan
Lung cancer test speeds growth of San Antonio's bioAffinity - Head Topics
New lung cancer test uses phlegm, machine learning to make early diagnoses - San Antonio Express-News
SA biomed to expand military market under new CFO - The Business Journals
bioAffinity Technologies names J. Michael Edwards as CFO - Investing.com India
bioAffinity Technologies names J. Michael Edwards as CFO By Investing.com - Investing.com Australia
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer - citybiz
bioAffinity Technologies Welcomes Back CFO for Future Growth - TipRanks
bioAffinity Technologies Appoints J. Michael Edwards as Chief Financial Officer - TechBullion
bioAffinity Technologies makes phlegm lung cancer test widely available to Veterans - Mugglehead
Maxim Group Initiates Coverage of bioAffinity Technologies (BIAF) with Buy Recommendation - MSN
BioAffinity Technologies : Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test Form 8 K - Marketscreener.com
bioAffinity Technologies Expands Access to Lung Cancer Test - TipRanks
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test - StockTitan
bioAffinity Technologies secures shareholder nod for warrant exercise - Investing.com
bioAffinity Technologies secures shareholder nod for warrant exercise By Investing.com - Investing.com UK
bioAffinity Technologies (NASDAQ:BIAFW) Shares Up 9.3% - Defense World
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis - BioSpace
BioAffinity Technologies Searching For New Finance Chief - MPO-mag
bioAffinity Technologies Searching for New Finance Chief - MPO-mag
bioAffinity Technologies announces secondary offering of 1.8M shares - MSN
Ratios Reveal: Breaking Down BioAffinity Technologies Inc (BIAF)’s Financial Health - The Dwinnex
bioAffinity Technologies Announces CFO Transition and Appointment - TipRanks
BioAffinity Names Michael Edwards as Interim CFO - MarketWatch
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO - Business Wire
bioAffinity Technologies (NASDAQ:BIAFW) Stock Price Up 7% - Defense World
Earnings roundup: Biglari hurt by investments; BioAffinity gains momentum - San Antonio Express-News
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024 - InvestorPlace
SEC Form 424B3 filed by bioAffinity Technologies Inc. - Quantisnow
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales - Manchestertimes
BioAffinity Technologies, Inc. announced that it has received $1.302084 million in funding - Marketscreener.com
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.48%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):